CA3057882A1 - Derives de dihydro-spiro-napthalene substitues et compositions pharmaceutiques connexes utiles comme inhibiteurs de la proteine mcl-1 - Google Patents
Derives de dihydro-spiro-napthalene substitues et compositions pharmaceutiques connexes utiles comme inhibiteurs de la proteine mcl-1 Download PDFInfo
- Publication number
- CA3057882A1 CA3057882A1 CA3057882A CA3057882A CA3057882A1 CA 3057882 A1 CA3057882 A1 CA 3057882A1 CA 3057882 A CA3057882 A CA 3057882A CA 3057882 A CA3057882 A CA 3057882A CA 3057882 A1 CA3057882 A1 CA 3057882A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical compositions
- mcl
- inhibitors
- protein
- napthalene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des inhibiteurs de la protéine de la leucémie à cellules myéloïdes 1 (Mcl-1), leurs procédés de préparation, des compositions pharmaceutiques associées, et leurs méthodes d'utilisation. L'invention concerne, par exemple, des composés de formule (I), des stéréoisomères de ceux-ci et des sels pharmaceutiquement acceptables de ces composés, ainsi que des compositions pharmaceutiques contenant lesdits composés. Les composés et les compositions de l'invention peuvent être utilisés, par exemple, dans le traitement de maladies ou d'états pathologiques tels que le cancer.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762479230P | 2017-03-30 | 2017-03-30 | |
| US201762479171P | 2017-03-30 | 2017-03-30 | |
| US62/479,171 | 2017-03-30 | ||
| US62/479,230 | 2017-03-30 | ||
| PCT/US2018/024723 WO2018183418A1 (fr) | 2017-03-30 | 2018-03-28 | Composés inhibant la protéine mcl-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3057882A1 true CA3057882A1 (fr) | 2018-10-04 |
Family
ID=61972255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3057882A Pending CA3057882A1 (fr) | 2017-03-30 | 2018-03-28 | Derives de dihydro-spiro-napthalene substitues et compositions pharmaceutiques connexes utiles comme inhibiteurs de la proteine mcl-1 |
Country Status (35)
| Country | Link |
|---|---|
| US (5) | US10300075B2 (fr) |
| EP (1) | EP3601297B9 (fr) |
| JP (2) | JP6453507B2 (fr) |
| KR (1) | KR102372322B1 (fr) |
| CN (1) | CN110691784B (fr) |
| AU (2) | AU2018244349B2 (fr) |
| BR (1) | BR112019020459B1 (fr) |
| CA (1) | CA3057882A1 (fr) |
| CL (1) | CL2019002777A1 (fr) |
| CO (1) | CO2019011762A2 (fr) |
| CR (1) | CR20190489A (fr) |
| DK (1) | DK3601297T5 (fr) |
| ES (1) | ES2940641T3 (fr) |
| FI (1) | FI3601297T3 (fr) |
| HR (1) | HRP20221412T2 (fr) |
| HU (1) | HUE060919T2 (fr) |
| IL (1) | IL269603B (fr) |
| JO (1) | JOP20190229B1 (fr) |
| LT (1) | LT3601297T (fr) |
| MX (1) | MX389487B (fr) |
| MY (1) | MY204294A (fr) |
| NZ (1) | NZ757606A (fr) |
| PE (1) | PE20200335A1 (fr) |
| PH (1) | PH12019502245A1 (fr) |
| PL (1) | PL3601297T3 (fr) |
| PT (1) | PT3601297T (fr) |
| RS (1) | RS63892B9 (fr) |
| SA (1) | SA519410222B1 (fr) |
| SG (1) | SG11201908945RA (fr) |
| SI (1) | SI3601297T1 (fr) |
| SM (1) | SMT202300122T1 (fr) |
| TW (1) | TWI685493B (fr) |
| UA (1) | UA124784C2 (fr) |
| UY (1) | UY37656A (fr) |
| WO (1) | WO2018183418A1 (fr) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI781136B (zh) | 2017-01-20 | 2022-10-21 | 美商阿克思生物科學有限公司 | 用於治療癌症相關病症之唑嘧啶 |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| SG11201908940UA (en) | 2017-03-30 | 2019-10-30 | Hoffmann La Roche | Isoquinolines as inhibitors of hpk1 |
| AR111307A1 (es) | 2017-03-30 | 2019-06-26 | Takeda Pharmaceuticals Co | Derivados de 1,2-dihidroespiro[ciclohexan-1,3-indol] o 1,2-dihidroespiro[ciclohexan-1,3-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa |
| MA49908A (fr) | 2017-08-18 | 2021-04-28 | Amgen Inc | Composés inhibant la protéine mcl-1 |
| US11279712B2 (en) | 2017-08-29 | 2022-03-22 | Amgen Inc. | Macrocyclic compounds that inhibit MCL-1 protein |
| US12041084B2 (en) | 2018-02-09 | 2024-07-16 | Bolster, Inc | Systems and methods for determining user intent at a website and responding to the user intent |
| US11301560B2 (en) * | 2018-02-09 | 2022-04-12 | Bolster, Inc | Real-time detection and blocking of counterfeit websites |
| US11271966B2 (en) * | 2018-02-09 | 2022-03-08 | Bolster, Inc | Real-time detection and redirecton from counterfeit websites |
| CN111818923A (zh) | 2018-02-16 | 2020-10-23 | 艾库斯生物科学有限公司 | 用唑并嘧啶化合物给药 |
| MA54985A (fr) | 2018-03-05 | 2021-12-29 | Amgen Inc | Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 |
| CN112118845B (zh) | 2018-05-14 | 2023-06-13 | 吉利德科学公司 | Mcl-1抑制剂 |
| TW202019905A (zh) | 2018-07-24 | 2020-06-01 | 瑞士商赫孚孟拉羅股份公司 | 異喹啉化合物及其用途 |
| TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| US11130769B2 (en) * | 2018-11-09 | 2021-09-28 | Prelude Therapeutics, Incorporated | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein |
| WO2020147802A1 (fr) * | 2019-01-18 | 2020-07-23 | Ascentage Pharma (Suzhou) Co., Ltd. | Spiroéthers macrocycliques utilisés en tant qu'inhibiteurs de mcl-1 |
| US12319703B2 (en) | 2019-01-23 | 2025-06-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrazoles as Mcl-1 inhibitors |
| CA3138058A1 (fr) | 2019-05-20 | 2020-11-26 | Matthew T. Burger | Conjugues anticorps-medicament inhibiteurs de mcl-1 et procedes d'utilisation |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| AU2020301161B2 (en) | 2019-06-25 | 2023-10-26 | Gilead Sciences, Inc. | FLT3L-Fc fusion proteins and methods of use |
| BR112022000251A2 (pt) * | 2019-07-09 | 2022-05-17 | Janssen Pharmaceutica Nv | Derivados macrocíclicos de espirociclo como inibidores de mcl-1 |
| KR102902719B1 (ko) | 2019-10-18 | 2025-12-24 | 포티 세븐, 엘엘씨 | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
| CA3153636A1 (fr) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Traitement d'un cancer du sang base sur une therapie anti-cd47 et anti-cd20 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| PT4065567T (pt) | 2019-11-26 | 2024-11-08 | Gilead Sciences Inc | Processos e intermediários para a preparação de inibidores de mcl1 |
| EP4445902A3 (fr) | 2019-12-24 | 2024-12-18 | Carna Biosciences, Inc. | Composés modulant la diacylglycérol kinase |
| CN117964757A (zh) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| JP2021161114A (ja) * | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Ｍｃｌ−１化合物のメチル化 |
| US20230212191A1 (en) * | 2020-04-16 | 2023-07-06 | Prelude Therapeutics, Incorporated | Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
| US12110294B2 (en) | 2020-05-01 | 2024-10-08 | Gilead Sciences, Inc. | CD73 compounds |
| KR20230006550A (ko) | 2020-05-06 | 2023-01-10 | 암젠 인크 | 비닐 보호된 알코올 중간체의 합성 |
| TWI867217B (zh) | 2020-05-06 | 2024-12-21 | 美商安進公司 | 乙烯基環丁基中間體之合成 |
| TWI827924B (zh) * | 2020-05-06 | 2024-01-01 | 美商安進公司 | 大環Mcl-1抑制劑中間體的閉環合成 |
| US20230136910A1 (en) * | 2020-05-06 | 2023-05-04 | Amgen Inc. | Synthesis of vinylic alcohol intermediates |
| BR112022022474A2 (pt) | 2020-05-06 | 2022-12-13 | Amgen Inc | Síntese de intermediários de sulfonamida |
| KR20230024287A (ko) * | 2020-05-13 | 2023-02-20 | 프렐루드 테라퓨틱스, 인코포레이티드 | 골수 세포 백혈병-1 (mcl-1) 단백질의 억제제로서의 스피로-술폰아미드 유도체 |
| CN115698023A (zh) * | 2020-06-10 | 2023-02-03 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环2-氨基-3-氟-丁-3-烯酰胺 |
| JP7825954B2 (ja) * | 2020-08-26 | 2026-03-09 | アムジエン・インコーポレーテツド | Ｍｃｌ－１阻害剤処方物 |
| MX2023002691A (es) | 2020-09-03 | 2023-05-03 | Amgen Inc | Desimetrización de diol mediante sustitución aromática nucleófila. |
| JP7659630B2 (ja) * | 2020-11-19 | 2025-04-09 | ギリアード サイエンシーズ， インコーポレイテッド | 大環状ｍｃｌ１阻害剤を調製するための方法及び中間体 |
| WO2022115451A1 (fr) | 2020-11-24 | 2022-06-02 | Novartis Ag | Conjugués anticorps-médicament inhibiteurs de mcl-1 et procédés d'utilisation |
| BR112023010228A2 (pt) * | 2020-11-25 | 2023-10-17 | Amgen Inc | Alquenilação enantiosseletiva de aldeídos |
| CN116670141A (zh) | 2020-12-17 | 2023-08-29 | 詹森药业有限公司 | 作为mcl-1抑制剂的大环支化3-氟-丁-3-烯酰胺 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| JP2024516641A (ja) | 2021-04-26 | 2024-04-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての大環状２－アリルテトラヒドロフラン |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| JP7673255B2 (ja) | 2021-06-11 | 2025-05-08 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| WO2022271650A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
| EP4359415A1 (fr) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
| WO2022271659A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
| EP4413165A1 (fr) | 2021-10-06 | 2024-08-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés de prédiction et d'amélioration de l'efficacité d'une thérapie par inhibiteur de mcl-1 |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| AU2022376954B2 (en) | 2021-10-29 | 2026-04-23 | Gilead Sciences, Inc. | Cd73 compounds |
| JP2024544570A (ja) | 2021-11-16 | 2024-12-03 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての大環状２－アミノ－ブト－３－エナミド |
| US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| WO2023107956A1 (fr) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Protéines se liant à nkg2d, cd16 et 5t4 |
| AU2022419982B2 (en) | 2021-12-22 | 2026-04-16 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3237577A1 (fr) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Agents de degradation des doigts de zinc de la famille ikaros et leurs utilisations |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023150249A1 (fr) | 2022-02-04 | 2023-08-10 | Amgen Inc. | Formes cristallines d'un inhibiteur de mcl-1 |
| AU2023215171A1 (en) * | 2022-02-04 | 2024-07-04 | Amgen Inc. | Crystalline salt and solvate forms of murizatoclax (amg 397) |
| EP4493554A1 (fr) | 2022-03-17 | 2025-01-22 | Gilead Sciences, Inc. | Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations |
| WO2023183817A1 (fr) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Polythérapie pour le traitement de cancers exprimant trop -2 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| PE20251072A1 (es) | 2022-05-20 | 2025-04-10 | Novartis Ag | Conjugados de anticuerpo-farmaco de compuestos antineoplasicos y metodos de uso de los mismos |
| PE20250758A1 (es) | 2022-07-01 | 2025-03-13 | Gilead Sciences Inc | Compuestos de cd73 |
| WO2024064668A1 (fr) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | POLYTHÉRAPIE ANTICANCÉREUSE PAR RAYONNEMENT IONISANT FOCAL ET PERTURBATION CD47/SIRPα |
| CN120225509A (zh) | 2022-12-22 | 2025-06-27 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (fr) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Inhibiteurs de parp7 |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| EP4516807A1 (fr) | 2023-08-28 | 2025-03-05 | Consorcio Centro de Investigación Biomédica en Red | Compositions destinées à être utilisées dans un procédé de fourniture d'une greffe améliorée de cellules souches hématopoïétiques |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| PY24103486A (es) | 2023-11-22 | 2025-06-06 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| TW202540186A (zh) | 2023-11-22 | 2025-10-16 | 瑞士商諾華公司 | 抗ｃｄ７抗體藥物結合物及其使用方法 |
| WO2025126157A1 (fr) | 2023-12-15 | 2025-06-19 | Advesya | Domaines de liaison anti-il-1rap et conjugués anticorps-médicament associés |
| WO2025137640A1 (fr) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Inhibiteurs azaspiro de wrn |
| WO2025245003A1 (fr) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| WO2026039365A1 (fr) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Composés de modulation de kras |
| WO2026089992A1 (fr) | 2024-10-21 | 2026-04-30 | Gilead Sciences, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| ES2705599T3 (es) | 2007-04-16 | 2019-03-26 | Abbvie Inc | Indoles sustituidos en la posición 7 como inhibidores de mcl-1 |
| EP3138838A1 (fr) | 2010-01-29 | 2017-03-08 | Dana-Farber Cancer Institute, Inc. | Petites molécules pour la modulation de mcl-1 et procédés de modulation de la mort cellulaire, la division cellulaire, la différenciation cellulaire et procédés de traitement de troubles |
| EP2751214B1 (fr) | 2011-08-31 | 2021-03-24 | Avery Dennison Corporation | Copolymères acrylate-oléfine adhésifs, leurs procédés de préparation et compositions les utilisant |
| WO2013052943A2 (fr) | 2011-10-06 | 2013-04-11 | The Regents Of The University Of Michgian | Inhibiteurs à petite molécule de mcl-1 et leurs utilisations |
| WO2013149124A1 (fr) | 2012-03-29 | 2013-10-03 | The Regents Of The University Of Michigan | Inhibiteurs de mcl-1 à petite molécule et utilisations de ceux-ci |
| JP6757312B2 (ja) * | 2014-03-27 | 2020-09-16 | ヴァンダービルト ユニバーシティー | 置換インドールｍｃｌ−１阻害剤 |
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| WO2017147410A1 (fr) * | 2016-02-25 | 2017-08-31 | Amgen Inc. | Composés inhibant la protéine mcl-1 |
| JP6786892B2 (ja) | 2016-06-09 | 2020-11-18 | 富士ゼロックス株式会社 | サーバ装置、情報処理システム及びプログラム |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| MA49908A (fr) | 2017-08-18 | 2021-04-28 | Amgen Inc | Composés inhibant la protéine mcl-1 |
| US11279712B2 (en) | 2017-08-29 | 2022-03-22 | Amgen Inc. | Macrocyclic compounds that inhibit MCL-1 protein |
-
2018
- 2018-03-27 JP JP2018059341A patent/JP6453507B2/ja active Active
- 2018-03-28 PT PT187178116T patent/PT3601297T/pt unknown
- 2018-03-28 SG SG11201908945R patent/SG11201908945RA/en unknown
- 2018-03-28 CR CR20190489A patent/CR20190489A/es unknown
- 2018-03-28 CA CA3057882A patent/CA3057882A1/fr active Pending
- 2018-03-28 CN CN201880035818.3A patent/CN110691784B/zh active Active
- 2018-03-28 RS RS20230036A patent/RS63892B9/sr unknown
- 2018-03-28 UA UAA201910703A patent/UA124784C2/uk unknown
- 2018-03-28 FI FIEP18717811.6T patent/FI3601297T3/fi active
- 2018-03-28 NZ NZ757606A patent/NZ757606A/en unknown
- 2018-03-28 US US15/938,001 patent/US10300075B2/en active Active
- 2018-03-28 LT LTEPPCT/US2018/024723T patent/LT3601297T/lt unknown
- 2018-03-28 SM SM20230122T patent/SMT202300122T1/it unknown
- 2018-03-28 PL PL18717811.6T patent/PL3601297T3/pl unknown
- 2018-03-28 SI SI201830809T patent/SI3601297T1/sl unknown
- 2018-03-28 MY MYPI2019005626A patent/MY204294A/en unknown
- 2018-03-28 EP EP18717811.6A patent/EP3601297B9/fr active Active
- 2018-03-28 MX MX2019011693A patent/MX389487B/es unknown
- 2018-03-28 WO PCT/US2018/024723 patent/WO2018183418A1/fr not_active Ceased
- 2018-03-28 HU HUE18717811A patent/HUE060919T2/hu unknown
- 2018-03-28 JO JOP/2019/0229A patent/JOP20190229B1/ar active
- 2018-03-28 AU AU2018244349A patent/AU2018244349B2/en active Active
- 2018-03-28 PE PE2019001963A patent/PE20200335A1/es unknown
- 2018-03-28 KR KR1020197029091A patent/KR102372322B1/ko active Active
- 2018-03-28 DK DK18717811.6T patent/DK3601297T5/da active
- 2018-03-28 HR HRP20221412TT patent/HRP20221412T2/hr unknown
- 2018-03-28 ES ES18717811T patent/ES2940641T3/es active Active
- 2018-03-28 BR BR112019020459-8A patent/BR112019020459B1/pt active IP Right Grant
- 2018-03-30 TW TW107111110A patent/TWI685493B/zh active
- 2018-04-02 UY UY0001037656A patent/UY37656A/es not_active Application Discontinuation
- 2018-12-11 JP JP2018231352A patent/JP6629419B2/ja active Active
-
2019
- 2019-03-11 US US16/297,904 patent/US10500213B2/en active Active
- 2019-08-22 US US16/547,747 patent/US10632128B2/en active Active
- 2019-09-24 IL IL269603A patent/IL269603B/en unknown
- 2019-09-27 CL CL2019002777A patent/CL2019002777A1/es unknown
- 2019-09-27 PH PH12019502245A patent/PH12019502245A1/en unknown
- 2019-09-30 SA SA519410222A patent/SA519410222B1/ar unknown
- 2019-10-24 CO CONC2019/0011762A patent/CO2019011762A2/es unknown
-
2020
- 2020-02-06 US US16/783,269 patent/US10821115B2/en active Active
- 2020-09-23 US US17/029,249 patent/US11224601B1/en active Active
-
2021
- 2021-01-15 AU AU2021200233A patent/AU2021200233A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
| UA118233C2 (uk) | Сполуки, які інгібують білок mcl-1 | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| PH12022551226A1 (en) | Pyrrolotriazine compounds acting as mnk inhibitor | |
| MX389597B (es) | Inhibidores de cdk2/4/6 de piridopirimidinona. | |
| MX2021004000A (es) | Derivados de piperidina. | |
| WO2019035914A8 (fr) | Inhibiteurs de mcl-1 macrocyclique et procédés d'utilisation | |
| TN2018000395A1 (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| WO2016164675A8 (fr) | Composés quinazoline substitués et leurs procédés d'utilisation | |
| WO2015200481A8 (fr) | Inhibiteurs de mnk et procédés associés | |
| EP3693369A3 (fr) | Inhibiteurs de bromodomaine | |
| EP4327877A3 (fr) | Inhibiteurs doubles de l'atm et de l'adn-pk destinés à être utilisés dans une thérapie antitumorale | |
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| PH12022550338A1 (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| SA522431777B1 (ar) | مشتقات ألفا -d- جالاكتو بيرانوسيد | |
| SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
| MX2020008498A (es) | Derivados de sobetirome. | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| CR20210181A (es) | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| MX2021004379A (es) | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen. | |
| WO2016112304A8 (fr) | Furoquinolinediones servant d'inhibiteurs de tdp2 | |
| TN2018000175A1 (en) | Indane derivatives as mglur7 modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220811 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250226 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250226 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250922 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250923 |